Acute Leukaemia Mini Panel (AML/ETO, INV[16], PML/RARA, BCR/ABL, TEL/AML1, MLL, E2A) Test: Booking, Price, and Results
About Acute Leukaemia Mini Panel (AML/ETO, INV[16], PML/RARA, BCR/ABL, TEL/AML1, MLL, E2A) Test: Booking, Price, and Results
| Field | Value |
|---|---|
| Also Known As | Acute Leukaemia Molecular Panel, AML/ALL Fusion Gene Panel, Leukaemia Translocation Panel, AML-ETO/INV16/PML-RARA/BCR-ABL/TEL-AML1/MLL/E2A Panel |
| Sample Type | Peripheral blood (EDTA tube) and bone marrow aspirate (sodium heparin tube) |
| Fasting Required | No — eat and drink normally before the test |
| Report Time | 15 days |
| Recommended For | Adults and children of any age when leukaemia is suspected; no gender restriction |
| Price | Starting at ₹21,600 |
What Is an Acute Leukaemia Mini Panel (AML/ETO, INV[16], PML/RARA, BCR/ABL, TEL/AML1, MLL, E2A) Test?
The Acute Leukaemia Mini Panel (AML/ETO, INV[16], PML/RARA, BCR/ABL, TEL/AML1, MLL, E2A) test is a specialised molecular diagnostic test. It uses Real Time PCR (a laboratory technique that identifies specific genetic material) to detect abnormal fusion genes linked to different types of acute leukaemia (blood cancer).
Doctors order this test when a patient shows signs of leukaemia or when routine blood reports show abnormal findings. It requires two sample types: a peripheral blood sample (drawn from a vein) and, in most cases, a bone marrow sample. It is also known as the Acute Leukaemia Molecular Panel or Leukaemia Translocation Panel.
What Does an Acute Leukaemia Mini Panel (AML/ETO, INV[16], PML/RARA, BCR/ABL, TEL/AML1, MLL, E2A) Test Measure?
The Acute Leukaemia Mini Panel (AML/ETO, INV[16], PML/RARA, BCR/ABL, TEL/AML1, MLL, E2A) test checks for seven specific genetic abnormalities. Each is linked to a distinct leukaemia subtype.
The table below summarises each marker and its significance.
| Marker | What It Indicates |
|---|---|
| AML1/ETO (RUNX1-RUNX1T1) | Linked to Acute Myeloid Leukaemia (AML); associated with a relatively favourable outcome |
| INV[16] (CBFB-MYH11) | An inversion of chromosome 16 is found in roughly 6 to 8% of adult AML cases; it generally carries a favourable prognosis |
| PML/RARA | A chromosomal translocation characteristic of Acute Promyelocytic Leukaemia (APL) |
| BCR/ABL | The Philadelphia chromosome marker; seen in Chronic Myeloid Leukaemia (CML) and a subset of Acute Lymphoblastic Leukaemia (ALL) |
| TEL/AML1 (ETV6-RUNX1) | The most common fusion gene in childhood B-cell ALL; linked to a favourable prognosis |
| MLL (KMT2A) rearrangement | Associated with aggressive leukaemia subtypes in both adults and children |
| E2A (TCF3) rearrangement | The E2A-PBX1 fusion is linked to favourable outcomes in childhood ALL |
Why Is an Acute Leukaemia Mini Panel (AML/ETO, INV[16], PML/RARA, BCR/ABL, TEL/AML1, MLL, E2A) Test Done?
A haematologist or oncologist may order this Acute Leukaemia Mini Panel test when a patient presents with certain signs or when initial blood investigations raise concern.
Common Symptoms That May Require This Test
The following symptoms are among the most common reasons a doctor requests this test.
- Persistent, unexplained tiredness or weakness
- Recurrent fever or night sweats
- Easy bruising or unusual bleeding
- Frequent infections that take longer than normal to clear
- Swollen lymph nodes (small glands in the neck, armpits, or groin)
- Unintentional weight loss
- Pale skin or pallor
Conditions This Test Can Help Detect
This panel helps classify a range of blood cancers. The conditions it can identify include the following.
- Acute Myeloid Leukaemia (AML), in which immature blood cells (blasts) crowd out healthy blood cells
- Acute Lymphoblastic Leukaemia (ALL), including B-cell and T-cell subtypes
- Acute Promyelocytic Leukaemia (APL), a specific AML subtype identified by the PML/RARA fusion
- Chronic Myeloid Leukaemia (CML) in blast crisis phase, identified via BCR/ABL
- Mixed phenotype acute leukaemia
Acute Leukaemia Mini Panel for Chronic Disease Monitoring
Once a leukaemia diagnosis is confirmed, this test is often repeated at intervals. It helps doctors track how well treatment is working and whether cancer cells with specific markers remain detectable. BCR/ABL monitoring is commonly used to assess response to targeted therapy in CML. Similarly, PML/RARA testing is repeated during and after APL treatment to detect minimal residual disease (tiny numbers of cancer cells that persist after treatment).
How to Prepare and What to Expect
Preparation for the Acute Leukaemia Mini Panel (AML/ETO, INV[16], PML/RARA, BCR/ABL, TEL/AML1, MLL, E2A) test is straightforward, though a few steps will help the process go smoothly.
Do You Need to Fast?
No fasting is required before this test. You can eat and drink as normal on the day of sample collection. There are no dietary restrictions specific to this panel.
Practical Tips Before Your Test
Keep the following points in mind before attending your appointment.
- Bring a detailed clinical history report, including your symptoms, previous test results, and family history, as this is required for the test.
- Bring any previous haematology reports or blood investigation results if you have them.
- Inform your doctor about all current medications and supplements, particularly any chemotherapy drugs.
- Wear loose-fitting or short-sleeved clothing for easy access to your arm during the blood draw.
- Avoid excessive caffeine, alcohol, and smoking in the hours before your appointment.
- Stay calm and relaxed; stress does not affect the test, but a calm state makes the procedure easier.
Step-by-Step Procedure
This test requires two types of samples. Here is what to expect for each.
Peripheral Blood Sample:
- A healthcare professional places a tourniquet (a soft elastic band) around your upper arm to make the vein more visible.
- The skin over the vein is cleaned with an antiseptic.
- A small needle is gently inserted, and approximately 3 ml of blood is drawn into a lavender-topped EDTA tube.
- The tourniquet is removed, the needle is withdrawn, and a cotton swab is pressed briefly over the site.
Bone Marrow Sample:
- A doctor numbs the skin and tissue at the back of your hip bone using a local anaesthetic injection.
- A fine needle is inserted to withdraw a small amount of liquid bone marrow (approximately 3 ml) into a green-topped sodium heparin tube.
- Both samples are labelled, stored under refrigeration (2 to 8 degrees Celsius), and dispatched promptly to the molecular laboratory for Real Time PCR analysis.
Factors That Can Affect Accuracy
Certain factors may influence how reliable the results are. These include the following.
- Recent blood transfusions, which may dilute leukaemic cells and reduce detection sensitivity
- Ongoing chemotherapy, which can affect the detectability of fusion gene transcripts
- Delayed transport of the sample to the laboratory, leading to sample degradation
- Poor sample collection technique at the time of the blood or marrow draw
- Quality and quantity of RNA or DNA extracted from the sample
Understanding Your Acute Leukaemia Mini Panel (AML/ETO, INV[16], PML/RARA, BCR/ABL, TEL/AML1, MLL, E2A) Test Results
Results from the Acute Leukaemia Mini Panel test are reported qualitatively: each marker is either Detected or Not Detected. A qualified haematologist or oncologist will interpret findings in the context of your full clinical picture.
| Parameter | Expected Result | What It Means |
|---|---|---|
| AML1/ETO | Not Detected | No AML-associated fusion gene found |
| INV[16]/CBFB-MYH11 | Not Detected | No chromosome 16 inversion detected |
| PML/RARA | Not Detected | No APL-linked translocation present |
| BCR/ABL | Not Detected | No Philadelphia chromosome marker found |
| TEL/AML1 | Not Detected | No fusion transcript associated with B-cell ALL |
| MLL rearrangement | Not Detected | No MLL gene rearrangement identified |
| E2A rearrangement | Not Detected | No E2A gene rearrangement identified |
Disclaimer: These ranges are general guidelines. Your doctor will interpret your results based on your age, health history, and other factors. Always consult a qualified healthcare professional for personalised medical advice.
A negative (Not Detected) result across all markers does not completely rule out leukaemia. Your doctor may recommend additional investigations if clinical suspicion remains. A positive (Detected) result on any marker provides important information about the leukaemia subtype and guides treatment planning.
Results During Special Conditions
A few circumstances can affect how results should be read.
Recent blood transfusions may lower the concentration of leukaemic cells in circulation, potentially reducing test sensitivity. Samples collected during or immediately after chemotherapy may show altered fusion gene levels, which can complicate interpretation. If sample transport is delayed, RNA can break down, which may produce a false-negative outcome.
How to Maintain Healthy Levels
For patients undergoing monitoring with this panel, the following general wellness steps support overall health during treatment.
- Attend all scheduled follow-up appointments with your haematologist or oncologist as advised.
- Report any new or worsening symptoms (such as unexplained bleeding, persistent fatigue, or fever) to your doctor promptly.
- Follow your prescribed treatment plan consistently and discuss any concerns with your care team.
Lupin Diagnostics Acute Leukaemia Mini Panel (AML/ETO, INV[16], PML/RARA, BCR/ABL, TEL/AML1, MLL, E2A) Test Price
The Acute Leukaemia Mini Panel (AML/ETO, INV[16], PML/RARA, BCR/ABL, TEL/AML1, MLL, E2A) test cost starts at ₹21,600 at Lupin Diagnostics. This test requires a visit to a Lupin Diagnostics centre; home collection is not available for this specialised molecular test.
The table below lists indicative prices across major Indian cities.
| City | Approximate Price (₹) |
|---|---|
| Mumbai | 21600 |
| Pune | 21600 |
| Bangalore | 21600 |
| Chennai | 21600 |
Disclaimer: Prices are indicative and may vary by location. Please confirm the current price at the time of booking.
How to Book
You can get an Acute Leukaemia Mini Panel test online booking by following these steps.
- Select the test on the Lupin Diagnostics website.
- Choose your city and preferred centre location.
- Visit the centre at your scheduled time for sample collection.
- Receive your report via email or WhatsApp within 15 days.
Frequently Asked Questions
This test identifies specific fusion genes and chromosomal abnormalities in the blood or bone marrow using Real Time PCR. It helps doctors diagnose the precise subtype of acute leukaemia and choose the most appropriate treatment. Results also help predict how likely a patient is to respond to a given therapy.
Doctors recommend this panel for patients who show symptoms suggestive of leukaemia (such as persistent fatigue, easy bruising, or frequent infections) or whose routine blood counts show unexplained abnormalities. It is suitable for both adults and children.
Two samples are typically required: a peripheral blood sample drawn from a vein in your arm and a bone marrow sample collected from the hip bone area. Both are taken at the diagnostic centre under clinical supervision.
No, the Acute Leukaemia Mini Panel test home collection is not available because this test requires specialised sample handling and clinical supervision for bone marrow collection. You will need to visit a Lupin Diagnostics centre.
Results are delivered within 15 days. The turnaround is longer than routine blood tests because the samples undergo complex Real Time PCR processing in a molecular laboratory.
A positive (Detected) result means that one or more of the tested fusion genes or chromosomal rearrangements are present in your sample. This information helps your doctor classify the type of leukaemia and plan treatment. A positive result should always be discussed with a haematologist or oncologist alongside other clinical findings.
No fasting is needed. However, you must bring a detailed clinical history, including your symptoms and any previous test reports, as this information is required for the test. Inform your doctor about all medications you are currently taking, especially chemotherapy drugs.
Acute Leukaemia Mini Panel (AML/ETO, INV[16], PML/RARA, BCR/ABL, TEL/AML1, MLL, E2A) Test: Booking, Price, and Results
